Ftse Mib
34.181,37
0,71%
DAX
18.053,81
0,73%
S&P 500
5.048,42
-0,46%
NASDAQ Composite
15.611,76
-0,64%
Bitcoin
64.431,34
-0,08%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistente personale
Home Investire Azioni U.S.A. NYSE Merck and Co Inc (MRK) Merck and Co Inc (MRK) Notizie

Merck and Co Inc

MRK
130,72
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:30:24
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202422:40IHMARKETNEWSU.S. Stocks Climb Well Off Worst Levels But Close Mostly..
25/4/202415:09IHMARKETNEWSFutures Pointing To Sharply Lower Open On Wall Street
25/4/202413:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
25/4/202412:30BWMerck Announces First-Quarter 2024 Financial Results
19/4/202413:04PRNCAHealth Canada Approves KEYTRUDA® as a first-line treatment..
10/4/202413:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/4/202412:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/4/202414:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/4/202412:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/3/202411:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/3/202411:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/3/202423:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/3/202411:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
19/3/202414:00BWMerck Announces Positive Data on V116, an Investigational,..
15/3/202421:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/3/202411:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/3/202408:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/3/202413:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
06/3/202416:25BWGilead and Merck Announce Phase 2 Data Showing an..
05/3/202415:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/3/202412:45BWMerck to Participate in the Barclays 26th Annual Global..
04/3/202412:45BWMerck to Participate in the Leerink Partners Global..
27/2/202412:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/2/202412:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
20/2/202422:14EDGAR2Form 8-K - Current report
20/2/202412:45BWFDA Grants Priority Review to Merck's Application for..
15/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:30EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:24EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:50EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:48EDGAR2Form 144 - Report of proposed sale of securities
12/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202413:05PRNCAHealth Canada Approves KEYTRUDA® in combination with..
09/2/202422:06EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202413:00PRNCAMERCK CANADA ANNONCE UNE COLLABORATION AVEC L'INSTITUT..
07/2/202422:09EDGAR2Form 144 - Report of proposed sale of securities
05/2/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202412:33PRNUSElanco Announces Sale of Aqua Business for $1.3 Billion
02/2/202422:35EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:09EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:08EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202412:39EDGAR2Form 8-K - Current report
01/2/202412:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
27/1/202416:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
26/1/202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
Apertura: Min: Max:
Chiusura: 130,72

La tua Cronologia

NYSE
MRK
Merck
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network